津药药业：盐酸甲氧氯普胺注射液获药品注册证书

Core Viewpoint - Tianyao Pharmaceutical (600488) announced that its subsidiary, Hubei Tianyao Pharmaceutical Co., Ltd., received the drug registration certificate for Metoclopramide Hydrochloride Injection from the National Medical Products Administration, indicating a significant regulatory approval for a key product in its portfolio [1] Company Summary - Tianyao Pharmaceutical's subsidiary has been granted approval for Metoclopramide Hydrochloride Injection, which is primarily used as an antiemetic [1] - The injection is indicated for various conditions including chemotherapy, radiotherapy, surgery, and other medical situations that may cause nausea and vomiting [1] - The product also aids in diagnostic procedures such as duodenal intubation and enhances the passage of barium during gastrointestinal X-ray examinations [1] Industry Summary - The approval of Metoclopramide Hydrochloride Injection highlights the ongoing demand for antiemetic medications in the healthcare sector, particularly in oncology and gastroenterology [1] - This development may enhance the competitive positioning of Tianyao Pharmaceutical within the pharmaceutical industry, especially in the antiemetic market segment [1]